Eli Lilly CEO Expresses Optimism for Foundayo's Growth in International Markets
Eli Lilly (LLY) CEO David Ricks expressed confidence that the company’s oral weight loss pill, Foundayo (orforglipron), will continue to gain market share as it expands beyond the U.S. Currently available in four countries, Ricks highlighted international markets as a key growth opportunity for the drug. Foundayo is part of Eli Lilly's expanding portfolio targeting obesity and related metabolic conditions. The company has seen strong demand for its weight loss treatments, including Zepbound (tirzepatide), which also serves dual purposes in diabetes management. Ricks emphasized that Foundayo’s launch outside the U.S. could further diversify revenue streams. The CEO's comments come amid growing interest from investors and analysts in Eli Lilly's obesity drug pipeline as a major growth driver for the company.
Tickers: $LLY